NCT04510636

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.

Detailed description

Pembrolizumab and bendamustine will be explored as a safe and effective treatment for these patients. Although current treatment options are available for patients in the relapsed state, once these therapies fail or are not tolerated, treatment options are quite limited. Pembrolizumab and bendamustine have both shown activity when used as a single agent as treatment for Hodgkin Lymphoma. Their side effect profiles also do not overlap, which makes them ideal to combine, with an intent to increase the amount and duration of complete responses while limiting the toxicities experienced by patients.

Conditions

• Classical Hodgkin Lymphoma
• Relapsed Cancer
• Refractory Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
DRUG	Bendamustine Hydrochloride	Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.

Timeline

• Start date: 2021-12-20
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2020-08-12
• Last updated: 2024-03-22

Locations

1 site across 1 country: Canada